/
Oncology
Advanced Hematologic Malignancies
13
Pipeline Programs↗
5
Active Trials↗
24
Companies Involved↗
Advanced Hematologic Malignancies is an emerging landscape with 13 programs across 24 companies. The most active players are Foghorn Therapeutics Inc., Kumquat Biosciences Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 112
Phase 21
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
92%
Small molecule
12 of 13 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 13 pipeline programs.
Analysis
Trial Status
29
clinical trials
Completed18 · 62%
Terminated5 · 17%
Recruiting3 · 10%
Active, not recruiting2 · 7%
Withdrawn1 · 3%
Clinical Trials
Trial Activity
29 trials
A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies
Recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 1·NCT07113925·114 enrolled
Infusional C-myb ASODN in Advanced Hematologic Malignancies
Completed·—·Phase 1·NCT00780052·13 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)